title: Anti-miR-362-3p Inhibits Migration and Invasion of Human Gastric Cancer Cells by Its Target CD82.
abstract: OBJECTIVE
  This study was to investigate the effects and mechanisms of miR-362-3p on regulation of gastric cancer (GC) cell metastasis potential.
  
  
  METHODS
  We detected miR-362-3p level in GC and adjacent normal tissues and investigated the relationship with clinicopathological factors. Next, we analyzed the level of miR-362-3p expression and CD82 in different differentiated GC cells compared with a normal gastric mucosa cell by RT-PCR and Western blot. Dual-luciferase reporter assay and Western blot confirmed a direct interaction between miR-362-3p and CD82 3'UTR. After miR-362-3p and CD82 were silenced in GC cells, we compared the transfected GC cells migration and invasion capacity by transwell assay. In addition, we detected the effects on cells angiogenesis by tube formation assay. Western blot was used to detect the impact of CD82 and miR-362-3p on epithelial-to-mesenchymal transition markers in treated GC cells.
  
  
  RESULTS
  Level of miR-362-3p expression was much higher in GC cells than in normal gastric mucosa cell, and miR-362-3p expression negatively correlated with CD82 mRNA expression in these cell lines. Furthermore, miR-362-3p expression induced [corrected] GC cell metastasis capacity by suppression of CD82 expression. Level of miR-362-3p may mediate E-cadherin, N-cadherin, and vimentin expression in GC cells.
  
  
  CONCLUSIONS
  This study illuminated that downregulation of miR-362-3p along with the upregulation of CD82 in GC cells resulted in the inhibition of GC migration and invasion. Thus, our results suggested that miR-362-3p or CD82 can be exploited as a new potential target for control of GC in the future.
authors: Department of Clinical Laboratory, Kunshan First People's Hospital, Affiliated to Jiangsu University, Kunshan, 215300, Jiangsu, China.
authors: Qing-Hui
authors: QH
authors: Zhang
authors: Yong-Liang
authors: YL
authors: Yao
authors: Xiao-Yang
authors: XY
authors: Wu
authors: Jian-Hong
authors: JH
authors: Wu
authors: Tao
authors: T
authors: Gu
authors: Ling
authors: L
authors: Chen
authors: Jin-Hua
authors: JH
authors: Gu
authors: Yun
authors: Y
authors: Liu
authors: Ling
authors: L
authors: Xu
mesh_terms: D000906:Antibodies; D002465:Cell Movement; D002478:Cells, Cultured; D005260:Female; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D051861:Kangai-1 Protein / Q000235:genetics / Q000378:metabolism*; D008297:Male; D035683:MicroRNAs / Q000235:genetics / Q000378:metabolism*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D034622:RNA Interference; D013270:Stomach / Q000166:cytology; D013274:Stomach Neoplasms / Q000378:metabolism*
chemical_list: D000906:Antibodies; C497688:CD82 protein, human; D051861:Kangai-1 Protein; C581582:MIRN362 microRNA, human; D035683:MicroRNAs
references: Nucleic Acids Res. 2005 Nov 27;33(20):e179
references: 16314309
references: Med Oncol. 2013;30(3):668
references: 23873015
references: Hum Exp Toxicol. 2015 Mar;34(3):260-5
references: 24925367
references: Cell Cycle. 2014;13(18):2962-74
references: 25486483
references: Cancer Biol Ther. 2014 May;15(5):544-59
references: 24553082
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Med Oncol. 2011 Dec;28 Suppl 1:S189-96
references: 21053104
references: Clin Cancer Res. 2013 Nov 1;19(21):5849-55
references: 24100626
references: Crit Rev Oncog. 2013;18(1-2):43-73
references: 23237552
references: Pathol Res Pract. 2014 May;210(5):285-90
references: 24553302
references: Anticancer Res. 2013 Oct;33(10):4431-8
references: 24123012
references: J Transl Med. 2014 Feb 05;12:33
references: 24495516
references: Int J Clin Exp Pathol. 2013 May 15;6(6):1060-7
references: 23696923
references: Hepatology. 2010 Jul;52(1):183-96
references: 20578262
references: Cancer Res. 1996 Oct 1;56(19):4387-90
references: 8813131
references: Oncogene. 2014 Apr 3;33(14 ):1755-63
references: 23604123
references: Cancer Sci. 2012 Apr;103(4):626-31
references: 22212856
references: Mol Med Rep. 2009 Nov-Dec;2(6):963-70
references: 21475928
references: Br J Cancer. 2010 Aug 10;103(4):532-41
references: 20664596
references: Arch Iran Med. 2012 Nov;15(11):707-12
references: 23102249
references: Mol Cancer Res. 2011 Jul;9(7):824-33
references: 21628394
references: Int J Biochem Cell Biol. 2013 Jun;45(6):1133-44
references: 23500527
references: Biochem Biophys Res Commun. 2014 Apr 4;446(2):541-8
references: 24613834
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: Mol Cancer. 2013 Sep 23;12(1):107
references: 24053443
references: Endocr Relat Cancer. 2014 Feb 01;21(1):113-25
references: 24402132
references: Int J Cancer. 2013 Jul;133(1):67-78
references: 23280316